drugset
drugset / Trial / NCT01935778

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

NCT01935778 ↗

Phase 3 Recruiting 286 enrolled Asan Medical Center Hallym University Medical Center · collabInha University Hospital · collabSeoul National University Bundang Hospital · collabSeverance Hospital · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer). S-1 and combined therapy of Capecitabine and Oxaliplatin are currently accepted as a standard therapy among the AGC patients who were performed gastrectomy from the D2 surgery. However, many improvements will be needed in stage IIIB and IV. Combined chemotherapy of Docetaxel, Capecitabine, and Oxaliplatin may be considered as one of the best treatments for IIB and IV(M0) stage AGC patients who were performed gastrectomy.

Timeline

Start
2013-10-02
Primary completion
2028-06-30
Completion
2028-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 800 mg/m2 Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Docetaxel Small molecule 60 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 100 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

No indication recorded.